Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation

Key facts

Sponsor

Pediatric Transplantation & Cellular Therapy Consortium

Principal Investigator

Michael Pulsipher, MD

Children's Hospital Los Angeles

Intervention

Virus Specific T-cell (VST) infusion(biological)

Enrollment

52 enrolled

Eligibility

All sexes

Timeline

2018 – 2025

Study locations (30)

• Phoenix Children's Hospital, Phoenix, Arizona, United States
• City of Hope, Duarte, California, United States
• University of California, Los Angeles, Los Angeles, California, United States
• Children's Hospital Los Angeles, Los Angeles, California, United States
• Stanford Lucile Packard Children's Hospital, Palo Alto, California, United States
• UCSF Medical Center, San Francisco, California, United States
• Children's Hospital Colorado, Aurora, Colorado, United States
• Yale, New Haven, Connecticut, United States
• Children's National Medical Center, Washington D.C., District of Columbia, United States
• Emory University/Children's Healthcare of Atlanta, Atlanta, Georgia, United States
• Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
• Riley Hospital for Children - Indiana University, Indianapolis, Indiana, United States
• Tufts Medical Center, Boston, Massachusetts, United States
• Dana-Farber Cancer Institute/ Boston Children's Hospital, Boston, Massachusetts, United States
• University of Michigan, Ann Arbor, Michigan, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.